Bio-XL is a preclinical-stage drug development company developing new drug entities based on in-licensed technologies, from the early stage to the late-clinical and commercial stages.The company is working toward an anticancer drug treatment based on the Klotho hormone, with a novel mechanism of action for triple-negative breast cancer and pancreatic cancer, as well as breast cancer prediction using digital pathology and artificial intelligence.Bio-XL has a worldwide exclusive license for the commercialization of the technologies based on intellectual property from Sheba Medical Center in Israel and Cedars-Sinai Medical Center in the U.S.